Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage biopharmaceutical company focused on developing FcRn inhibitor therapies for autoimmune and inflammatory diseases. The company went public in 2019 and operates primarily within the immunology and rare-disease therapeutic sectors. On August 28, 2025, Immunovant filed an 8-K current report with the SEC under accession number 0001764013-25-000132, disclosing a material event to investors and the public. The company's lead pipeline asset, batoclimab, has been the subject of ongoing clinical development across multiple indications. Investors and analysts tracking Immunovant's regulatory milestones and corporate disclosures can access the full filing details and historical data on SpacDesk — sign up at SpacDesk.com for complete coverage.